Systemic inflammatory response plays a crucial role in septic shock, and the removal of inflammatory factors through extracorporeal blood purification may improve patient outcomes. In this study, the investigators propose a novel blood purification mode - Adaptive Blood Purification (ABP) to evaluate its impact on the prognosis and organ function of patients with septic shock. ABP is a blood purification mode: when a patient with septic shock has no indication for renal replacement therapy (RRT), only coupled filtration and adsorption (CPFA) is used to adsorb inflammatory factors. When accompanied by acute kidney injury and meeting the indications for RRT, plasma filtration adsorption dialysis (CPFA + RRT, PFAD) is applied. According to a randomized, open-label, multi-center, parallel-controlled trial design, patients with early septic shock in the intensive care units were randomly divided into a control group and a treatment group at a 1:1 ratio. The control group received standard treatment by the "Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021", while the treatment group received two 6-hour ABP treatments within 24 hours of enrollment on the basis of standard treatment. Sequential Organ Failure Assessment (SOFA) scores were recorded at 0h, day 1 to day 7 after enrollment, and plasma pro-inflammatory factors (TNF- α, IL-6, IL-8), anti-inflammatory factors (IL-4, IL-10) and and late-stage inflammatory factor (HMGB1) were tested. A 90-day all-cause mortality rate was followed up, and finally, the clinical efficacy of ABP was evaluated.